GLG Inc’s Amicus Therapeutics FOLD Stock Holding History

GLG Inc’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-23,851	Closed	-$56K	–	729
2013 Q2	$56K	Buy	+23,851	New	+$73.3K	﹤0.01%	628

Other funds holding FOLD

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SEP

Sound Energy Partners Greenwich, Connecticut $49.5M AUM 35.64% 1-Year Est. Return

GLG Inc's FOLD Position: Q3 2013 in Review

GLG Inc sold out of Amicus Therapeutics (FOLD) in Q3 2013, closing a stake of 23,851 shares — an estimated $56K sold.

GLG Inc first reported a position in FOLD in Q2 2013 and held it in 1 quarter. The position peaked at $56K in Q2 2013. 72 funds tracked by Wall St. Rank hold FOLD as of Q3 2013.

GLG Inc reported no remaining Amicus Therapeutics position as of Q3 2013 after selling out during the quarter.
GLG Inc sold 23,851 Amicus Therapeutics shares in Q3 2013, an estimated $56K.
GLG Inc first reported a position in Amicus Therapeutics in Q2 2013 and held it in 1 quarter.
GLG Inc's Amicus Therapeutics position peaked at $56K in Q2 2013.
72 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2013.

Based on GLG Inc's 13F filing for Q3 2013, filed 14 Nov 2013.